Anders Valind
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Anders Valind has a total of 102 co-authors. Here are the top co-authors by number of shared publications:
- David Gisselsson
Division of Clinical Genetics, Department of Laboratory Medicine Lund University Lund Sweden
86 shared publications - Jenny Karlsson
Division of Clinical Genetics, Department of Laboratory Medicine Lund University Lund Sweden
81 shared publications - Natalie Andersson
Division of Clinical Genetics, Department of Laboratory Medicine Lund University Lund Sweden
72 shared publications - Subhayan Chattopadhyay
Division of Clinical Genetics, Department of Laboratory Medicine, Lund University, Lund, Sweden
71 shared publications - Alexandra Petersson
Division of Oncology and Therapeutic Pathology, Department of Clinical Sciences, Lund University, Lund, Sweden
70 shared publications - Karin Jirström
Division of Oncology and Therapeutic Pathology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden
70 shared publications
Latest Publications
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Table S3 from Resolving the Pathogenesis of Anaplastic Wilms Tumors through Spatial Mapping of Cancer Cell Evolution
Supplementary Table 3. Table. Sample list with TP53 status. All 20 WT cases and their corresponding samples are listed. ‘Sample position’ refers to the individual sample and its position in a certain paraffin block (see Figure 1 for details.) IR= intermediate risk, BT= blastemal type, DA= diffuse anaplasia. Headings marked in grey show TP53 sequencing results; wt=wild type, mut=mutation, NA= not annotated (i.e. not sequenced), aa= amino acid, REF= reference nucleotide, ALT= alternative nucleotide, TP53 ref= number of wild type TP53 alleles, TP53 mut=number of TP53 mutated alleles. Genomic positions according to hg19. In all columns with grey headings (except column ‘TP53’), semicolons (;) denote when more than one unique TP53 mutation is present in the same tumor sample.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S3 from Resolving the Pathogenesis of Anaplastic Wilms Tumors through Spatial Mapping of Cancer Cell Evolution
Supplementary Table 3. Table. Sample list with TP53 status. All 20 WT cases and their corresponding samples are listed. ‘Sample position’ refers to the individual sample and its position in a certain paraffin block (see Figure 1 for details.) IR= intermediate risk, BT= blastemal type, DA= diffuse anaplasia. Headings marked in grey show TP53 sequencing results; wt=wild type, mut=mutation, NA= not annotated (i.e. not sequenced), aa= amino acid, REF= reference nucleotide, ALT= alternative nucleotide, TP53 ref= number of wild type TP53 alleles, TP53 mut=number of TP53 mutated alleles. Genomic positions according to hg19. In all columns with grey headings (except column ‘TP53’), semicolons (;) denote when more than one unique TP53 mutation is present in the same tumor sample.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Table S1 from Resolving the Pathogenesis of Anaplastic Wilms Tumors through Spatial Mapping of Cancer Cell Evolution
Supplementary Table 1. Overview of the study cohort and the clinical data. This table contains basic clinical information, including age, sex, whether tumors were uni- or bilateral, histology, stage, risk group, treatment to which the resection specimen analyzed was subjected to, the final outcome and the record of adverse events.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from Resolving the Pathogenesis of Anaplastic Wilms Tumors through Spatial Mapping of Cancer Cell Evolution
Supplementary Table 1. Overview of the study cohort and the clinical data. This table contains basic clinical information, including age, sex, whether tumors were uni- or bilateral, histology, stage, risk group, treatment to which the resection specimen analyzed was subjected to, the final outcome and the record of adverse events.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S1 from Resolving the Pathogenesis of Anaplastic Wilms Tumors through Spatial Mapping of Cancer Cell Evolution
Supplementary Figure 1 Geographic overview of histological and genetic features.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Resolving the Pathogenesis of Anaplastic Wilms Tumors through Spatial Mapping of Cancer Cell Evolution
Supplementary Figure 1 Geographic overview of histological and genetic features.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Fig S3 from Resolving the Pathogenesis of Anaplastic Wilms Tumors through Spatial Mapping of Cancer Cell Evolution
Supplementary Figure 3. Relationship between anaplasia, copy number aberrations, regression and mitotic rate.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFig S3 from Resolving the Pathogenesis of Anaplastic Wilms Tumors through Spatial Mapping of Cancer Cell Evolution
Supplementary Figure 3. Relationship between anaplasia, copy number aberrations, regression and mitotic rate.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Table S2 from Resolving the Pathogenesis of Anaplastic Wilms Tumors through Spatial Mapping of Cancer Cell Evolution
Supplementary Table 2. Representativeness of study participants. Details on how the patients with Wilms tumor in the present study compare to the general population of patients diagnosed with with Wilms tumor.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 from Resolving the Pathogenesis of Anaplastic Wilms Tumors through Spatial Mapping of Cancer Cell Evolution
Supplementary Table 2. Representativeness of study participants. Details on how the patients with Wilms tumor in the present study compare to the general population of patients diagnosed with with Wilms tumor.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Fig S2 from Resolving the Pathogenesis of Anaplastic Wilms Tumors through Spatial Mapping of Cancer Cell Evolution
Supplementary Figure 2. Complexity of phylogenetic tree, comparing WT DA to IR and BT WT.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFig S2 from Resolving the Pathogenesis of Anaplastic Wilms Tumors through Spatial Mapping of Cancer Cell Evolution
Supplementary Figure 2. Complexity of phylogenetic tree, comparing WT DA to IR and BT WT.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Table S4 from Resolving the Pathogenesis of Anaplastic Wilms Tumors through Spatial Mapping of Cancer Cell Evolution
Supplementary Table 4. Segmental aberrations. All 20 Wilms tumor (WT) cases and their corresponding samples are listed. ‘Sample position’ refers to the individual sample and its position in a certain paraffin block (see Figure 1 for details.) For each genetic event the following information is given: the ploidy level (Ploidy), chromosome (chr), the genomic start and end positions, genetic events annotated as gain, loss, CNNI (copy neutral imbalance) or homozygous loss, the length of the aberration (bp), which chromosomal cytoband, the median log2 ratio, allelic composition and mutated cell fraction (MCF). IR= intermediate risk, BT= blastemal type, DA= diffuse anaplasia. Genomic positions accordning to hg19.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S4 from Resolving the Pathogenesis of Anaplastic Wilms Tumors through Spatial Mapping of Cancer Cell Evolution
Supplementary Table 4. Segmental aberrations. All 20 Wilms tumor (WT) cases and their corresponding samples are listed. ‘Sample position’ refers to the individual sample and its position in a certain paraffin block (see Figure 1 for details.) For each genetic event the following information is given: the ploidy level (Ploidy), chromosome (chr), the genomic start and end positions, genetic events annotated as gain, loss, CNNI (copy neutral imbalance) or homozygous loss, the length of the aberration (bp), which chromosomal cytoband, the median log2 ratio, allelic composition and mutated cell fraction (MCF). IR= intermediate risk, BT= blastemal type, DA= diffuse anaplasia. Genomic positions accordning to hg19.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Data from Resolving the Pathogenesis of Anaplastic Wilms Tumors through Spatial Mapping of Cancer Cell Evolution
Purpose:While patients with intermediate-risk (IR) Wilms tumors now have an overall survival (OS) rate of almost 90%, those affected by high-stage tumors with diffuse anaplasia have an OS of only around 50%. We here identify key events in the pathogenesis of diffuse anaplasia by mapping cancer cell evolution over anatomic space in Wilms tumors.Experimental Design:We spatially mapped subclonal landscapes in a retrospective cohort of 20 Wilms tumors using high-resolution copy-number profiling and TP53 mutation analysis followed by clonal deconvolution and phylogenetic reconstruction. Tumor whole-mount sections (WMS) were utilized to characterize the distribution of subclones across anatomically distinct tumor compartments.Results:Compared with non-diffuse anaplasia Wilms tumors, tumors with diffuse anaplasia showed a significantly higher number of genetically distinct tumor cell subpopulations and more complex phylogenetic trees, including high levels of phylogenetic species richness, divergence, and irregularity. All regions with classical anaplasia showed TP53 alterations. TP53 mutations were frequently followed by saltatory evolution and parallel loss of the remaining wild-type (WT) allele in different regions. Morphologic features of anaplasia increased with copy-number aberration (CNA) burden and regressive features. Compartments demarcated by fibrous septae or necrosis/regression were frequently (73%) associated with the emergence of new clonal CNAs, although clonal sweeps were rare within these compartments.Conclusions:Wilms tumors with diffuse anaplasia display significantly more complex phylogenies compared with non-diffuse anaplasia Wilms tumors, including features of saltatory and parallel evolution. The subclonal landscape of individual tumors was constrained by anatomic compartments, which should be considered when sampling tissue for precision diagnostics.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from Resolving the Pathogenesis of Anaplastic Wilms Tumors through Spatial Mapping of Cancer Cell Evolution
Purpose:While patients with intermediate-risk (IR) Wilms tumors now have an overall survival (OS) rate of almost 90%, those affected by high-stage tumors with diffuse anaplasia have an OS of only around 50%. We here identify key events in the pathogenesis of diffuse anaplasia by mapping cancer cell evolution over anatomic space in Wilms tumors.Experimental Design:We spatially mapped subclonal landscapes in a retrospective cohort of 20 Wilms tumors using high-resolution copy-number profiling and TP53 mutation analysis followed by clonal deconvolution and phylogenetic reconstruction. Tumor whole-mount sections (WMS) were utilized to characterize the distribution of subclones across anatomically distinct tumor compartments.Results:Compared with non-diffuse anaplasia Wilms tumors, tumors with diffuse anaplasia showed a significantly higher number of genetically distinct tumor cell subpopulations and more complex phylogenetic trees, including high levels of phylogenetic species richness, divergence, and irregularity. All regions with classical anaplasia showed TP53 alterations. TP53 mutations were frequently followed by saltatory evolution and parallel loss of the remaining wild-type (WT) allele in different regions. Morphologic features of anaplasia increased with copy-number aberration (CNA) burden and regressive features. Compartments demarcated by fibrous septae or necrosis/regression were frequently (73%) associated with the emergence of new clonal CNAs, although clonal sweeps were rare within these compartments.Conclusions:Wilms tumors with diffuse anaplasia display significantly more complex phylogenies compared with non-diffuse anaplasia Wilms tumors, including features of saltatory and parallel evolution. The subclonal landscape of individual tumors was constrained by anatomic compartments, which should be considered when sampling tissue for precision diagnostics.
- Open Access
- 20 November 2025
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 73 (2) , e32168
Early Toxicity in Childhood Acute Lymphoblastic Leukemia: A Comparison of NOPHO ALL2008 and ALLTogether Protocols in Sweden
Background: The European ALLTogether protocol for childhood acute lymphoblastic leukemia, initiated in Sweden 2019, introduced earlier asparaginase during induction, dexamethasone instead of prednisone for all patients, and omitted anthracyclines from low‐risk induction to reduce treatment‐related toxicity. Consolidation‐1 was based on the Induction 1B‐phase developed by the BFM‐group, replacing mercaptopurine, methotrexate, and asparaginase used in the previous NOPHO ALL2008 protocol, ALL2008. Following implementation, early treatment toxicity was considered unacceptably high, prompting a protocol amendment. We compared the prevalence of 14 predefined toxicities, the number of inpatient days, and weight changes during induction and consolidation‐1 between the two protocols. Methods: We conducted a population‐based cohort study in Sweden, reviewing patient records from 117 children treated under ALLTogether protocol and 234 matched controls under ALL2008 protocol. Results: The mean number of toxicities per patient was similar between the protocols (2.5 [290/117] vs. 2.3 [547/234]). ALLTogether cohort had significantly greater weight gain, with over 50% experiencing a > 10% increase ( p < 0.01). Hyperglycemia (OR 5.17, 95% CI 1.93–13.82) and osteonecrosis (3.4% vs. 0%, p = 0.012) were more common, while liver dysfunction (0.59, 0.38–0.93) was less frequent in the ALLTogether protocol. The number of inpatient days was similar across protocols, except for the initial hospitalization, which was longer in ALLTogether (median 11 vs. 7 days, p < 0.01). Conclusions: The early introduction of asparaginase likely contributed to increased weight gain, hyperglycemia, and osteonecrosis. While overall toxicity burden remained similar between protocols, the shift in toxicity profile may explain the perception of increased early toxicity during treatment with the ALLTogether protocol. Trial Registration: ClinicalTrials.gov identifier: NCT03911128; EudraCT numbers: 2018‐001795‐38 and 2008‐003235‐20
- 20 November 2025
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 73 (2) , e32168
Open AccessEarly Toxicity in Childhood Acute Lymphoblastic Leukemia: A Comparison of NOPHO ALL2008 and ALLTogether Protocols in Sweden
Background: The European ALLTogether protocol for childhood acute lymphoblastic leukemia, initiated in Sweden 2019, introduced earlier asparaginase during induction, dexamethasone instead of prednisone for all patients, and omitted anthracyclines from low‐risk induction to reduce treatment‐related toxicity. Consolidation‐1 was based on the Induction 1B‐phase developed by the BFM‐group, replacing mercaptopurine, methotrexate, and asparaginase used in the previous NOPHO ALL2008 protocol, ALL2008. Following implementation, early treatment toxicity was considered unacceptably high, prompting a protocol amendment. We compared the prevalence of 14 predefined toxicities, the number of inpatient days, and weight changes during induction and consolidation‐1 between the two protocols. Methods: We conducted a population‐based cohort study in Sweden, reviewing patient records from 117 children treated under ALLTogether protocol and 234 matched controls under ALL2008 protocol. Results: The mean number of toxicities per patient was similar between the protocols (2.5 [290/117] vs. 2.3 [547/234]). ALLTogether cohort had significantly greater weight gain, with over 50% experiencing a > 10% increase ( p < 0.01). Hyperglycemia (OR 5.17, 95% CI 1.93–13.82) and osteonecrosis (3.4% vs. 0%, p = 0.012) were more common, while liver dysfunction (0.59, 0.38–0.93) was less frequent in the ALLTogether protocol. The number of inpatient days was similar across protocols, except for the initial hospitalization, which was longer in ALLTogether (median 11 vs. 7 days, p < 0.01). Conclusions: The early introduction of asparaginase likely contributed to increased weight gain, hyperglycemia, and osteonecrosis. While overall toxicity burden remained similar between protocols, the shift in toxicity profile may explain the perception of increased early toxicity during treatment with the ALLTogether protocol. Trial Registration: ClinicalTrials.gov identifier: NCT03911128; EudraCT numbers: 2018‐001795‐38 and 2008‐003235‐20
- Open Access
- 22 October 2025
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 73 (1) , e32120
Infectious Complications During Early Treatment of Childhood Acute Lymphoblastic Leukemia—A Comparison Between the ALLTogether and NOPHO ALL‐2008 Protocols
Introduction: Infection remains the most common treatment‐related toxicity of childhood ALL, emphasizing the need to identify patients at risk and to tailor treatment strategies accordingly. Aims: The primary aim was to compare infectious toxicity during early treatment for childhood ALL following the ALLTogether and NOPHO ALL‐2008 (ALL‐2008) protocols, and second, to identify risk factors for infectious toxicity. Methods: A national retrospective matched cohort study was conducted, including 345 patients aged 1–17 years diagnosed with ALL and treated in Sweden according to the ALLTogether or ALL‐2008 protocols. Nonparametric tests were used to compare infectious outcomes between protocols, and regression modeling was used to identify risk factors of the infectious outcomes. Results: Treatment following ALL‐2008 showed higher infectious toxicity during induction, whereas treatment following ALLTogether showed increased infectious toxicity during consolidation 1. Overall, treatment according to ALL‐2008 was associated with a higher incidence of infections. Anthracycline use and young age (1–9 years) were associated with both higher infectious incidence and more severe infectious complications. Dexamethasone was associated with both lower incidence and lower severity of infectious complications as compared to prednisone. Conclusions: A notable shift in the timing of infectious toxicity was observed between the two treatment protocols. Risk factors for infectious toxicity during early treatment include anthracycline use and young age. Dexamethasone as an induction steroid was associated with lower infectious burden, although its effect is difficult to isolate from the simultaneous anthracycline effect. The findings suggest that treatment composition plays a central role in determining both the extent and timing of infectious complications.
- 22 October 2025
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 73 (1) , e32120
Open AccessInfectious Complications During Early Treatment of Childhood Acute Lymphoblastic Leukemia—A Comparison Between the ALLTogether and NOPHO ALL‐2008 Protocols
Introduction: Infection remains the most common treatment‐related toxicity of childhood ALL, emphasizing the need to identify patients at risk and to tailor treatment strategies accordingly. Aims: The primary aim was to compare infectious toxicity during early treatment for childhood ALL following the ALLTogether and NOPHO ALL‐2008 (ALL‐2008) protocols, and second, to identify risk factors for infectious toxicity. Methods: A national retrospective matched cohort study was conducted, including 345 patients aged 1–17 years diagnosed with ALL and treated in Sweden according to the ALLTogether or ALL‐2008 protocols. Nonparametric tests were used to compare infectious outcomes between protocols, and regression modeling was used to identify risk factors of the infectious outcomes. Results: Treatment following ALL‐2008 showed higher infectious toxicity during induction, whereas treatment following ALLTogether showed increased infectious toxicity during consolidation 1. Overall, treatment according to ALL‐2008 was associated with a higher incidence of infections. Anthracycline use and young age (1–9 years) were associated with both higher infectious incidence and more severe infectious complications. Dexamethasone was associated with both lower incidence and lower severity of infectious complications as compared to prednisone. Conclusions: A notable shift in the timing of infectious toxicity was observed between the two treatment protocols. Risk factors for infectious toxicity during early treatment include anthracycline use and young age. Dexamethasone as an induction steroid was associated with lower infectious burden, although its effect is difficult to isolate from the simultaneous anthracycline effect. The findings suggest that treatment composition plays a central role in determining both the extent and timing of infectious complications.